SARS-CoV-2-specific ELISA development

J Immunol Methods. Sep-Oct 2020;484-485:112832. doi: 10.1016/j.jim.2020.112832. Epub 2020 Aug 8.

Abstract

Critical to managing the spread of COVID-19 is the ability to diagnose infection and define the acquired immune response across the population. While genomic tests for the novel Several Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) detect the presence of viral RNA for a limited time frame, when the virus is shed in the upper respiratory tract, tests able to define exposure and infection beyond this short window of detectable viral replication are urgently needed. Following infection, antibodies are generated within days, providing a durable read-out and archive of exposure and infection. Several antibody tests have emerged to diagnose SARS-CoV-2. Here we report on a qualified quantitative ELISA assay that displays all the necessary characteristics for high-throughput sample analysis. Collectively, this test offers a quantitative opportunity to define both exposure and levels of immunity to SARS-CoV-2.

MeSH terms

  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • Antibodies, Viral / isolation & purification
  • Betacoronavirus / immunology
  • Betacoronavirus / isolation & purification*
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques / methods*
  • Coronavirus Infections / blood
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / virology
  • Enzyme-Linked Immunosorbent Assay*
  • Feasibility Studies
  • High-Throughput Screening Assays
  • Humans
  • Pandemics
  • Pneumonia, Viral / blood
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / virology
  • Reproducibility of Results
  • SARS-CoV-2
  • Sensitivity and Specificity
  • Time Factors

Substances

  • Antibodies, Viral